ReviewERJ open research2021
Targeted therapy in eosinophilic chronic obstructive pulmonary disease.
Review in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Biologics in Older Adults with Chronic Obstructive Pulmonary Disease: A Narrative Review.Journal of clinical medicine · 2026Review
- Review
- The impact of neoadjuvant chemoimmunotherapy on pulmonary function in non-small cell lung cancer patients.Translational lung cancer research · 2026Article
- Pre-COPD: Impact on prevention, detection, and treatment.Presse medicale (Paris, France : 1983) · 2026Review
- Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD.Frontiers in immunology · 2026Review
- Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy.Frontiers in immunology · 2026Review
- COPD 2.0: Bronchodilators, biologics and beyond - A systematic review.Lung India : official organ of Indian Chest Society · 2026Article
- Type 2 Inflammation in Asthma and COPD: Biomarkers, Clinical Applications, and Targeted Therapies.Journal of inflammation research · 2026Review
- Chronic Obstructive Pulmonary Disease in Never-Smokers-A Distinct Entity Within the COPD Spectrum.Life (Basel, Switzerland) · 2025Review
- The Role of Interleukin-13 in Chronic Airway Diseases: A Cross-Sectional Study in COPD and Asthma-COPD Overlap.Diseases (Basel, Switzerland) · 2025Article
- Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.Pulmonary therapy · 2025Review
- Inhibition of IL-4Rα reduces CCL26 in bronchial epithelial cells from COPD patients.ERJ open research · 2025Article
- Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies.Biomolecules · 2025Review
- Disease Onset and Burden in Patients With Chronic Bronchitis and COPD: A Real-World Evidence Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Dupilumab for the treatment of COPD: protocol for a systematic review and meta-analysis.Frontiers in medicine · 2025Article
- The Burden of COPD with Type 2 Inflammation in North-West Continental Europe.International journal of chronic obstructive pulmonary disease · 2025Review
- Serum T2-High Inflammation Mediators in Eosinophilic COPD.Biomolecules · 2024Article
- Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- What every clinician should know about inflammation in COPD.ERJ open research · 2024Review
- Current Perspectives of Pharmacotherapies for COPD.Respiratory care · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a common and preventable airway disease causing significant worldwide mortality and morbidity. Lifetime exposure to tobacco smoking and environmental particles are the two major risk factors. Over recent decades, COPD has become a growing public health problem with an increase in incidence. COPD is defined by airflow limitation due to airway inflammation and small airway remodelling coupled to parenchymal lung destruction. Most patients exhibit neutrophil-predominant airway inflammation combined with an increase in macrophages and CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.